Medical Condition News

RSS

Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications

Daiichi Sankyo Company, Limited, announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

3 Feb 2010

BRAF drugs may accelerate tumour growth in cancer patients with faulty RAS gene

A team of UK scientists has made the unexpected discovery that drugs which target a well known fault in a protein called BRAF could actually fuel the progression of cancer in some cases. The findings of this study, which was jointly funded by Cancer Research UK, The Institute of Cancer Research (ICR) and the Wellcome Trust are published in Cell.

3 Feb 2010

Ambassadors of Purple selected to help promote Purple Day for Epilepsy

As the third annual, worldwide Purple Day for Epilepsy approaches on March 26, 2010, organizers in Canada and in 15 other participating countries around the globe are looking for volunteers to promote epilepsy awareness in local communities.

3 Feb 2010

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.

3 Feb 2010

Innovative discharge program reduces congestive heart failure readmissions

An innovative discharge program developed by Saddleback Memorial Medical Center combining coordination of hospital and community resources, strong patient education and the IDEAL LIFE Bluetooth-enabled wireless remote health monitoring system has helped to reduce congestive heart failure (CHF) readmissions by 50 percent

3 Feb 2010

Penn Medicine experts available to offer medical insight and commentary during 2010 Winter Olympics

Experts from the University of Pennsylvania School of Medicine are available to offer expert medical insight and commentary during the 2010 Winter Olympics in Vancouver on issues ranging from the effects of performance enhancing drugs to concerns about the spread of novel H1N1, head trauma and more.

3 Feb 2010

Go Red For Women launches nationwide call inviting women to Speak Up about heart disease

Too many women die each year because they are unaware that heart disease is their No. 1 killer. Right now, one in three women die of cardiovascular disease and 90 percent of women have one or more risk factors for developing heart disease in the future.

3 Feb 2010

Iodoprovidone exhibits safety and efficiency in management of malignant pleural effusion

In the USA each year, 200,000 cancer patients suffer from a malignant pleural effusion - development of excessive fluid (pleural effusion) in the chest. Several litres of such fluid can accumulate, and many patients suffer from significant breathlessness and distress. One in four patients with lung cancer, one in every three with breast cancer and most of the patients with mesothelioma will develop a malignant effusion.

3 Feb 2010

LLS increases maximum benefit for myeloma patients to $10,000

The Leukemia & Lymphoma Society (LLS) is pleased to announce that, effective Feb. 1, 2010, patients with myeloma and waldenstrom macroglobulinemia will now be able to receive up to $10,000 in support to help offset the costs of prescription drug co-pays and other insurance related expenses.

3 Feb 2010

Certain cancer surgeries for low-risk patients may be performed at community hospitals

Low-risk patients who require certain cancer surgeries can have the procedures performed with low operative mortality rates at community hospitals, according to a new study.

3 Feb 2010

Apple Valley Medical Center to hold free Heart Failure Community Education Evening

A free Heart Failure Community Education Evening will be held from 6:00 p.m. to 8:00 p.m. on Tuesday, February 9, 2010, at the Apple Valley Medical Center.

3 Feb 2010

Research retraction underscores the safety and efficacy of MMR vaccines

The Lancet, a premier British medical journal, today retracted a study published in 1998 that drew a link between the measles, mumps and rubella (MMR) vaccine and increased incidence of autism.

3 Feb 2010

Is there a link to rising rates of autism, ADHD and other learning and developmental disabilities?

Jeff Sell, father of twin sons with autism ,Vice President for Policy at the Autism Society; Maureen H. Swanson, Healthy Children Project Coordinator, Learning Disabilities Association of America; Larry Silver MD, author of the Understanding and Coping with Your Child's Learning Disabilities; and others will join Andy Igrejas, National Campaign Director of the Safer Chemicals, Healthy Families Campaign on a national telephone news briefing for the release of Mind, Disrupted: How Toxic Chemicals May Affect How We Think and Who We Are, produced by the Learning and Developmental Disabilities Initiative (LDDI).

3 Feb 2010

Research opens new avenues for understanding genetic basis of type 2 diabetes

Together with colleagues in Barcelona, researchers at the University of North Carolina at Chapel Hill have generated a complete map of the areas of the genome that control which genes are "turned on" or "off."

3 Feb 2010

TGen, Horizon Discovery partner in development of novel cancer cell-lines

The Translational Genomics Research Institute (TGen) and Horizon Discovery today announced plans to develop human disease models for use in TGen's cancer research.

3 Feb 2010

Nanotope’s bioactive nanofiber system promotes cartilage regeneration

Arrowhead Research Corporation today announced publication in Proceedings of the National Academy of Sciences (PNAS) of a study using Nanotope’s lead compound for cartilage regeneration. The study’s authors, which include Nanotope co-founder Dr. Samuel Stupp, showed that Nanotope’s bioactive nanofiber system promotes the growth of new cartilage in a rabbit model. The treatment is engineered to repair cartilage defects by working with an animal’s own bone marrow stem cells to stimulate the production of new natural cartilage.

3 Feb 2010

Baker's yeast promising against cancer

A researcher at Charles Drew University of Medicine and Science is investigating the potential use of non-pathogenic baker's yeast as a promising, natural therapy for cancer.

3 Feb 2010

Cancer survivors become advocates for other cancer patients

Sociologists at Case Western Reserve University found that when passive cancer patients become survivors, they have plenty of bold advice to offer other cancer patients, according to a study in JAGS, the Journal of American Geriatric Society.

3 Feb 2010

Hypertension drug market to decrease through 2013 due to generic erosion and few emerging therapies

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to extensive generic erosion, the hypertension drug market will be constrained through 2018 by a pipeline containing very few emerging therapies with novel mechanisms of action. Gilead's darusentan was positioned to be the next emerging therapy with a novel mechanism of action to reach the hypertension market. However, following darusentan's failure to meet its primary endpoint in the recent DORADO-AC Phase III clinical trial, further development of the agent has been terminated.

3 Feb 2010

Video campaign teaches parents on how to minimize risk from toxic chemicals

Chronic childhood illnesses – asthma, allergies, autism, cancer, obesity and diabetes – are plaguing our nation, and credible scientific evidence links chemical exposure to many of these conditions.

3 Feb 2010

Medical Condition News

Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications

BRAF drugs may accelerate tumour growth in cancer patients with faulty RAS gene

Ambassadors of Purple selected to help promote Purple Day for Epilepsy

AMPYRA for MS: Acorda Therapeutics announces wholesale pricing and patient assistance program

Innovative discharge program reduces congestive heart failure readmissions

Penn Medicine experts available to offer medical insight and commentary during 2010 Winter Olympics

Go Red For Women launches nationwide call inviting women to Speak Up about heart disease

Iodoprovidone exhibits safety and efficiency in management of malignant pleural effusion

LLS increases maximum benefit for myeloma patients to $10,000

Certain cancer surgeries for low-risk patients may be performed at community hospitals

Apple Valley Medical Center to hold free Heart Failure Community Education Evening

Research retraction underscores the safety and efficacy of MMR vaccines

Is there a link to rising rates of autism, ADHD and other learning and developmental disabilities?

Research opens new avenues for understanding genetic basis of type 2 diabetes

TGen, Horizon Discovery partner in development of novel cancer cell-lines

Nanotope’s bioactive nanofiber system promotes cartilage regeneration

Baker's yeast promising against cancer

Cancer survivors become advocates for other cancer patients

Hypertension drug market to decrease through 2013 due to generic erosion and few emerging therapies

Video campaign teaches parents on how to minimize risk from toxic chemicals

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Modular cleanrooms: Enhancing flexibility and compliance

Latest News